Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00134498 · ClinicalTrials.gov registry record · Phase 3

A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides

A Phase 3 study of Hypertriglyceridemia and Hyperlipoproteinemia Type IV, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
160
Enrollment target
20
Study locations

NCT00134498 is a Phase 3 study of Hypertriglyceridemia and Hyperlipoproteinemia Type IV that has completed, run by Pfizer. The registered enrollment target is 160 participants, roughly in line with the 170-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target. The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00134498, a Phase 3 study of Hypertriglyceridemia and Hyperlipoproteinemia Type IV, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
160 participants
Enrollment target
20
Study locations

Study Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.

Conditions Studied

Hypertriglyceridemia Hyperlipoproteinemia Type IV

Interventions

  • DRUG atorvastatin
  • DRUG torcetrapib/atorvastatin

Study Locations (20)

California

  • Pfizer Investigational Site - Anaheim
  • Pfizer Investigational Site - Huntington Beach
  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Orange
  • Pfizer Investigational Site - Orangevale
  • Pfizer Investigational Site - Pacific Palisades
  • Pfizer Investigational Site - Studio City
  • Pfizer Investigational Site - Tustin
  • Pfizer Investigational Site - Walnut Creek

Florida

  • Pfizer Investigational Site - Hollywood
  • Pfizer Investigational Site - Longwood
  • Pfizer Investigational Site - West Palm Beach

Connecticut

  • Pfizer Investigational Site - Farmington

District of Columbia

  • Pfizer Investigational Site - Washington D.C.

Hawaii

  • Pfizer Investigational Site - Tripler AMC

Illinois

  • Pfizer Investigational Site - Chicago

Indiana

  • Pfizer Investigational Site - Indianapolis

Kansas

  • Pfizer Investigational Site - Overland Park

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2005-02
Est. Completion 2006-11
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00134498

The ClinicalTrials.gov registry entry for NCT00134498 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 170-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which atorvastatin is the first listed.

NCT00134498 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00134498 about?

NCT00134498 is a clinical study titled "A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides". The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.

What is the current status of trial NCT00134498?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2005-02. Estimated completion is 2006-11.

What conditions does trial NCT00134498 study?

This clinical trial studies the following conditions: Hypertriglyceridemia, Hyperlipoproteinemia Type IV.

What interventions are being tested in trial NCT00134498?

The interventions under investigation include: atorvastatin (DRUG), torcetrapib/atorvastatin (DRUG).

Who is sponsoring clinical trial NCT00134498?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00134498 being conducted?

This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertriglyceridemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertriglyceridemia

All registered trials for this condition

Hyperlipoproteinemia Type IV

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.